Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06491043

Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of Umc119-06-05 Intravenous Infusion For The Treatment Of Subjects With Moderate To Severe Chronic Obstructive Pulmonary Disease

Sponsor: Meribank Biotech Co., Ltd.

Conditions Chronic Obstructive Pulmonary Disease

Interventions UMC119-06-05

Updated 3 times since 2024 Last updated: Jul 5, 2024 Started: Jun 11, 2024 Primary completion: Dec 30, 2026 Completion: Dec 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Obstructive Pulmonary Disease and is currently actively recruiting participants. Meribank Biotech Co., Ltd. leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2

First recorded

Jun 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Meribank Biotech Co., Ltd.

Data source: Meribank Biotech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Taipei City, Taiwan
• Taoyuan, Taiwan